|1.||Melzer, Nima: 8 articles (11/2015 - 01/2011)|
|2.||Harenberg, Job: 8 articles (11/2015 - 09/2002)|
|3.||Bramlage, Peter: 7 articles (01/2014 - 12/2010)|
|4.||Riess, Hanno: 6 articles (12/2014 - 08/2003)|
|5.||Haas, Sylvia: 6 articles (02/2011 - 08/2003)|
|6.||Brom, Joachim: 4 articles (01/2006 - 08/2003)|
|7.||Weidinger, Gottfried: 4 articles (01/2006 - 08/2003)|
|8.||Harenberg, J: 4 articles (06/2002 - 04/2000)|
|9.||Kakkar, Ajay K: 3 articles (03/2012 - 10/2005)|
|10.||Abletshauser, C: 3 articles (11/2011 - 06/2010)|
11/01/2011 - "Certoparin and UFH were equally effective and safe with a reduced risk of minor bleeding complications with certoparin in the very elderly."
01/01/2013 - "Two patients treated with certoparin had recurrent DVT and one had PE (one patient with minor bleeding). "
01/01/2013 - "We aimed to verify safety and effectiveness of certoparin real-world use and to identify predictors of thromboembolic events or bleeding. "
11/01/2011 - "The risk of any (OR 0.45; 95%CI 0.26-0.79) and minor bleeding (OR 0.42; 95%CI 0.23-0.78) was reduced with certoparin in the very elderly only. "
06/01/2011 - "In two multivariable regression models certoparin and immobilisation <10 days were associated with less bleeding while a GFR ≤30 ml/min/1.73 m2 was associated with increased bleeding. "
07/01/2013 - "Certoparin has proved to be effective and safe therapy for preventing venous thromboembolism in different surgical and medical settings. "
07/01/2013 - "Specifically, the authors review studies on the pharmacological characteristics of certoparin and the clinical trial and post-marketing studies in the field of venous thromboembolism. "
07/01/2013 - "Certoparin represents a valid option for venous thromboembolism prevention and DVT treatment. "
01/01/2013 - "Reason for certoparin use was prophylaxis of venous thromboembolism in 1331 (94.6%) patients and treatment in 76 (5.4%) patients. "
03/01/2012 - "Venous thromboembolism occurrence was not different between treatment groups in TOPIC-1 (4% treated with certoparin, 7 of 174 vs 4% receiving placebo, 7 of 177, odds ratio [OR] 1.02; 95% confidence interval [CI] 0.30-3.48) and in TOPIC-2 (4.5%, 12 of 268) vs 8.3%, 22 of 264, respectively, OR 0.52; CI 0.23-1.12). "
|3.||Body Weight (Weight, Body)
06/01/2008 - "Treatment with certoparin was stopped only after two consecutive days with INR values >2. The objective was to document the feasibility and safety of a short-term treatment with a fixed, body weight-independent certoparin regimen (2 x 8000 U anti-Xa). "
10/01/2003 - "Patients with acute symptomatic proximal DVT (n=1758), proven by ascending phlebography or compression ultrasound, received either a fixed, body weight independent dose of 8,000 IU Certoparin b.i.d. "
08/01/2003 - "Thromboembolic events were equally distributed in body weight categories with < 50, 50-80 and >80 kg as followed: 0, 3.6% and 4.1% of patients for the Certoparin group and 0, 4.6% and 4.2% of patients for the UFH group. "
09/01/2002 - "After the subcutaneous administration of 8000 IU Certoparin, pharmacodynamic parameters did not differ between patients and healthy volunteers, and the AUC of the anticoagulant effects were not related to body weight. "
06/01/2008 - "Certoparin administered at 8000 U anti-Xa twice daily independent of body weight was safe and appeared to be effective in patients with non-valvular AF undergoing electrical cardioversion. "
01/01/2006 - "Certoparin (3000 U anti-Xa OD) is at least as effective and safe as UFH (TID) for the prevention of thromboembolic complications in patients with acute ischemic stroke."
01/01/2006 - "Overall, 545 patients were randomized within 24 hours of stroke onset to treatment with certoparin (3000 U anti-Xa OD; n=272) or UFH (5000 U TID; n=273) for 12 to 16 days. "
01/01/2001 - "Dose increase of certoparin up to 8000 U aXa twice daily did not improve the functional outcome of patients with ischemic stroke. "
01/01/2001 - "To study the safety and efficacy of the low-molecular-weight heparin certoparin, we performed a randomized, double-blind, dose-finding multicenter trial in patients with acute ischemic stroke (Therapy of Patients With Acute Stroke [TOPAS]). "
01/01/2006 - "Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial."
07/01/2013 - "Unfortunately, certoparin has no specific data from clinical trials on treatment of pulmonary embolism. "
10/05/2005 - "Because of a severe pulmonary embolism in one study patient, an interim analysis was performed, and the dosage of certoparin was increased to 3,000 IU twice daily. "
12/01/2014 - "These data suggest that the recommendation for the use of certoparin in the treatment of isolated DVT can safely be extended to treatment of DVT in patients concomitantly suffering from pulmonary embolism."
12/01/2014 - "In the group of patients without pulmonary embolism at baseline, 2.82% of patients treated with certoparin (23/816) and 4.63% of patients treated with UFH (37/800) had a venous thromboembolic event (RR = 0.61, CI = 0.37-1.02). "
12/01/2014 - "After 6 months of follow-up, 6.58% of patients with pulmonary embolism at baseline treated with certoparin (5/76) compared with 11.5% of patients with pulmonary embolism at baseline treated with UFH (7/61) had a venous thromboembolic event [relative risk (RR) = 0.57, confidence interval (CI) = 0.19-1.72]. "
|1.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|3.||Dalteparin (Dalteparin Sodium)
|5.||Nadroparin (Nadroparin Calcium)
|6.||Biological Markers (Surrogate Marker)
|2.||Renal Dialysis (Hemodialysis)
|3.||Electric Countershock (Cardioversion)
|4.||Hip Replacement Arthroplasty (Total Hip Replacement)